DOĞAN, İ. Et Al. 2022. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib. CLINICAL CANCER INVESTIGATION JOURNAL , no.4 , 5-9.

DOĞAN, İ., Khanmammadov, N., Ahmed, M. A., Yildiz, A., Saip, P., Aydiner, A., ... VATANSEVER, S.(2022). Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib. CLINICAL CANCER INVESTIGATION JOURNAL , no.4, 5-9.

DOĞAN, İzzet Et Al. "Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib," CLINICAL CANCER INVESTIGATION JOURNAL , no.4, 5-9, 2022

DOĞAN, İzzet Et Al. "Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib." CLINICAL CANCER INVESTIGATION JOURNAL , no.4, pp.5-9, 2022

DOĞAN, İ. Et Al. (2022) . "Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib." CLINICAL CANCER INVESTIGATION JOURNAL , no.4, pp.5-9.

@article{article, author={İzzet DOĞAN Et Al. }, title={Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib}, journal={CLINICAL CANCER INVESTIGATION JOURNAL}, year=2022, pages={5-9} }